Premium
Role of Second Transplantation for Children With Acute Myeloid Leukemia Following Posttransplantation Relapse
Author(s) -
Taga Takashi,
Murakami Yoshitaka,
Tabuchi Ken,
Adachi Souichi,
Tomizawa Daisuke,
Kojima Yasuko,
Kato Koji,
Koike Kazutoshi,
Koh Katsuyoshi,
Kajiwara Ryosuke,
Hamamoto Kazuko,
Yabe Hiromasa,
Kawa Keisei,
Atsuta Yoshiko,
Kudo Kazuko
Publication year - 2016
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25866
Subject(s) - medicine , hematopoietic stem cell transplantation , myeloid leukemia , transplantation , complete remission , leukemia , bone marrow , disease , myeloid , pediatrics , oncology , chemotherapy
Background In children with acute myeloid leukemia (AML), hematopoietic stem cell transplantation (HSCT) in first remission is indicated for patients with a relatively high risk of relapse. Second HSCT is a curative option; however, few reports have been published about a second HSCT in children for AML with posttransplantation relapse. Procedure Using the database provided by the Japanese Society of Hematopoietic Cell Transplantation, we analyzed 46 children with AML who underwent a second allogeneic HSCT after achieving a second remission. Results The median duration from the first to second HSCT was 20 months, and the source of the second HSCT was related bone marrow (BM) in 22, related peripheral blood in 6, unrelated BM in 14, and unrelated cord blood in 4 patients. Twenty‐five children eventually died of the following causes: progressive disease in 14 and transplant‐related toxicities in 9. The 5‐year overall survival rate was 41.7 ± 7.7%. An interval of less than 24 months between the first and second HSCT was a significant poor prognostic factor. Conclusions Children with AML who experience a relapse after HSCT in first remission have a good chance of survival with a second HSCT if a second remission is achieved.